EUVIMEDEUVIMED entdecken
Crossref

Investigation of Substance Basis and Pharmacodynamics of Qingzao Jiufei Decoction in Lung Cancer Based On Serum Pharmacochemistry and Proteomics

Xiaoli Wen iD, Biting Cheng, Min Tan, Xiang Zhang, Ziheng Yao, Rumei Huang, Ge Zhang, Ling Liu, Fangyan Cai, Hongning Liu iD

Chemistry & Biodiversity · 2025

DOI: 10.1002/cbdv.202402774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Xiaoli Wen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Drugs, Chinese Herbal, Proteomics. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Science and Technology Research Project of Jiangxi Provincial Department of Education, Science and Technology Project of the State Administration of Traditional Chinese Medicine, Major Project Cultivation Project of Jiangxi University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Qingzao Jiufei Decoction ( QD ) is a renowned prescription for nourishing lung Yin to treat lung‐related diseases in ancient and modern times. It has been reported that QD can effectively inhibit the growth of lung cancer (LC), but the material basis and mechanism of its treatment of LC remain to be further studied. In this experiment, we combined serum pharmacochemistry and proteomics to study the pharmacodynamic material basis and mechanism of QD against LC. The results showed that in vitro a total of 121 compounds were identified. A total of 33 prototype chemical components were identified in vivo, which may be effective active ingredients for QD treatment of LC. Proteomic experiments have shown that compared with the model group, 113 DEPs in LC tissues were significantly changed after QD treatment, among which 57 proteins were significantly up‐regulated and 56 proteins were significantly down‐regulated ( p < 0.05). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed on these DEPs. A total of 205 pathways were enriched, and the PI3K–Akt signaling pathway was experimentally verified. The results showed that QD can be used to treat LC by inhibiting the activation of the PI3K/Akt/mTOR signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrugs, Chinese HerbalProteomicsHumansAnimalsCell ProliferationSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktMiceMale

Stichwörter der Autor:innen

Qingzao Jiufei Decoction (QD)lung cancer (LC)pharmacodynamic material basisproteomicsserum pharmacochemistry

Substanzen

Drugs, Chinese HerbalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Research Center for Differentiation and Development of CM Basic Theory of Jiangxi University of Chinese Medicine, Jiangxi Province Key Laboratory of CM Etiopathogenesis, Nanchang, Jiangxi, China.
  • Nanchang Medical College, Nanchang, Jiangxi, China.

ORCID-Profile: Xiaoli Wen, Hongning Liu

Förderung

  • Science and Technology Research Project of Jiangxi Provincial Department of Education
  • Science and Technology Project of the State Administration of Traditional Chinese Medicine
  • Major Project Cultivation Project of Jiangxi University of Traditional Chinese Medicine
  • Major Incremental and Decremental Expenditure Project of the Central Government
  • Science and Technology Project of Jiangxi Provincial Administration of Traditional Chinese Medicine
  • Jiangxi Provincial Higher Education School Innovation and Entrepreneurship Training Programme
  • Student Innovation and Entrepreneurship Project of Jiangxi University of Chinese Medicine
  • Science and Technology Programme Project of the Administration of Traditional Chinese Medicine of Jiangxi Province

Zitieren

APA

Wen, X., Cheng, B., Tan, M., Zhang, X., Yao, Z., Huang, R., Zhang, G., Liu, L., Cai, F., & Liu, H. (2025). Investigation of Substance Basis and Pharmacodynamics of Qingzao Jiufei Decoction in Lung Cancer Based On Serum Pharmacochemistry and Proteomics. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202402774

Vancouver

Wen X, Cheng B, Tan M, Zhang X, Yao Z, Huang R, et al. Investigation of Substance Basis and Pharmacodynamics of Qingzao Jiufei Decoction in Lung Cancer Based On Serum Pharmacochemistry and Proteomics. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202402774

BibTeX
@article{Wen2025,
  author = {Wen, Xiaoli and Cheng, Biting and Tan, Min and Zhang, Xiang and Yao, Ziheng and Huang, Rumei and Zhang, Ge and Liu, Ling and Cai, Fangyan and Liu, Hongning},
  title = {Investigation of Substance Basis and Pharmacodynamics of Qingzao Jiufei Decoction in Lung Cancer Based On Serum Pharmacochemistry and Proteomics},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  doi = {10.1002/cbdv.202402774}
}
Kostenlos starten →